世界人工智能大会:分子之心发布10大解决方案 AI蛋白设计迈入“可编程”时代

Core Insights - The AI protein design company "MoleculeOS," founded by Xu Jinbo, showcased significant advancements at the WAIC 2025, marking a breakthrough in the AI protein design field [1][3] Group 1: Technology and Innovation - MoleculeOS is an industry-grade AI protein infrastructure platform that integrates the world's first multimodal AI protein foundation model, NewOrigin (Darwin), along with over ten leading AI protein prediction, optimization, and design technologies [1] - The platform demonstrates superior performance, surpassing AlphaFold 3 in complex structure prediction, achieving not only comparable accuracy but also improved physical properties for better antigen-antibody and enzyme-substrate complex predictions [3] - MoleculeOS has significantly enhanced molecular simulation precision and efficiency, achieving a million-fold increase in efficiency, reaching industrial-grade levels [3] Group 2: Industry Applications - The platform has been optimized to meet industry demands, offering automated workflows for drug design, enzyme design, and various other applications, including antibody design and enzyme stability [4] - MoleculeOS has been validated in multiple industrial projects, addressing real-world needs in innovative drug design and synthetic biology, allowing for customized protein design with a single click [4] Group 3: Accessibility and Impact - MoleculeOS features a conversational AI agent, enabling biologists without an AI background to design high-value molecules quickly and accurately, thus lowering the technical barrier [6] - The traditional methods of protein design are time-consuming and have low success rates, but AI integration offers a transformative approach, significantly improving research efficiency and success rates in drug development [6] - MoleculeOS aims to empower biologists by freeing them from tedious laboratory tasks, allowing them to focus on strategic design and judgment, ultimately leading to safer, more effective drugs and lower-cost bioproducts [6]